Power doppler endoscopic ultrasound for the assessment of pancreatic neuroendocrine tumors

Iordache, Sevastiţa; Angelescu, Radu; Filip, Monalisa; Costache, M; Popescu, CarmenFlorina; Gheonea, Dan-Ionuţ; Săftoiu, Adrian

doi:10.4103/2303-9027.117735

Cited by 13 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results demonstrated that LHT could attenuate the proliferation of pancreatic cancer without cytotoxicity. Moreover, the inhibiting effect of LHT on the proliferation of RINm cells was stronger than those in the PANC1 or MIA PaCa-2 cells, which might be dependent on the characteristics of pancreatic cancer cells; PNETs have much abundant blood vessels in tumor tissue [ 46 , 47 , 48 ]. Therefore, we conducted the following studies to analyze the effect of LHT on the function of pancreatic cancer.…”

Section: Resultsmentioning

confidence: 99%

Anticancer Effect of Heparin–Taurocholate Conjugate on Orthotopically Induced Exocrine and Endocrine Pancreatic Cancer

Hwang

Jeong

Yun

et al. 2021

Cancers

View full text Add to dashboard Cite

Pancreatic cancers are classified based on where they occur, and are grouped into those derived from exocrine and those derived from neuroendocrine tumors, thereby experiencing different anticancer effects under medication. Therefore, it is necessary to develop anticancer drugs that can inhibit both types. To this end, we developed a heparin–taurocholate conjugate, i.e., LHT, to suppress tumor growth via its antiangiogenic activity. Here, we conducted a study to determine the anticancer efficacy of LHT on pancreatic ductal adenocarcinoma (PDAC) and pancreatic neuroendocrine tumor (PNET), in an orthotopic animal model. LHT reduced not only proliferation of cancer cells, but also attenuated the production of VEGF through ERK dephosphorylation. LHT effectively reduced the migration, invasion and tube formation of endothelial cells via dephosphorylation of VEGFR, ERK1/2, and FAK protein. Especially, these effects of LHT were much stronger on PNET (RINm cells) than PDAC (PANC1 and MIA PaCa-2 cells). Eventually, LHT reduced ~50% of the tumor weights and tumor volumes of all three cancer cells in the orthotopic model, via antiproliferation of cancer cells and antiangiogenesis of endothelial cells. Interestingly, LHT had a more dominant effect in the PNET-induced tumor model than in PDAC in vivo. Collectively, these findings demonstrated that LHT could be a potential antipancreatic cancer medication, regardless of pancreatic cancer types.

show abstract

Section: Resultsmentioning

confidence: 99%

Anticancer Effect of Heparin–Taurocholate Conjugate on Orthotopically Induced Exocrine and Endocrine Pancreatic Cancer

Hwang

Jeong

Yun

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…[13] Pancreatic adenocarcinomas are in general hypoenhanced in both the arterial and late venous phases, while pseudotumoral chronic pancreatitis or neuroendocrine tumors are either isoenhanced or hyperenhanced in the arterial phase as compared to the surrounding parenchyma. [1,[14][15][16][17][18] Taking into consideration hypoenhancement as a predictive factor for pancreatic carcinoma, our study demonstrated that CE-EUS (arterial phase) has sensitivity, specificity, and accuracy of 98.57%, 77.78%, and 92.78%, respectively. For CE-EUS in the venous phase, the values of sensitivity, specificity, and accuracy were 98.57%, 66.67%, and 89.69%, respectively.…”

Section: Discussionmentioning

confidence: 99%

Clinical impact of strain histogram EUS elastography and contrast-enhanced EUS for the differential diagnosis of focal pancreatic masses: A prospective multicentric study

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background: Recent advances in EUS techniques (real-time EUS elastography and contrast-enhanced EUS) have allowed a better characterization of focal pancreatic masses. Mean strain histograms (SHs) are considered a good parameter for the semi-quantitative evaluation of focal pancreatic masses, alongside complementary contrast-enhanced EUS parameters which can be quantified during both the early arterial and late venous phase. Materials and Methods: The study design was prospective, blinded, and multicentric, assessing real-time EUS elastography and contrast-enhanced EUS results for the characterization of focal pancreatic masses using parametric measurements, in comparison with pathology which is the gold standard. SHs were performed based on the embedded software of the ultrasound system, with the values being reversed as opposed to our initially published data on hue histograms. Consequently, a cutoff of 80 was derived from previous multicentric trials. Contrast-enhanced EUS also allowed the focal masses to be classified as hyper-, iso-, or hypoenhanced in comparison with the normal pancreatic parenchyma. EUS-FNA was then performed for all patients, with a positive cytological diagnosis taken as a final proof of malignancy for the pancreatic masses. The diagnoses obtained by EUS-FNA were verified further either by surgery or during a clinical follow-up of at least 6 months. Results: A total number of 97 consecutive patients with focal pancreatic masses were included in the study. Based on previously defined cutoffs of 80, the values of sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of the mean SHs for the diagnosis of pancreatic cancer were 100%, 29.63%, 78.65%, 100%, and 80.41%, respectively. Corresponding values for contrast-enhanced EUS (taking into consideration hypoenhencement as a

show abstract

“…These results demonstrated that LHT could attenuate the proliferation of pancreatic cancer without cytotoxicity. Moreover, the inhibition effect of LHT on the proliferation of RINm cells was stronger than those in the PANC1 or MIA PaCa-2 cells, which might be dependent on the characteristics of pancreatic cancer cells; PNETs have much abundant blood vessels in tumor tissue 22,23,24 . Therefore, we conducted the following studies to analyze the different mechanisms depending on the type of pancreatic cancer.…”

Section: Lht Effect On Various Kinds Of Pancreatic Cancer Cellsmentioning

confidence: 95%

Anti-cancer effect of orally absorbable heparin on orthotopically induced exocrine and endocrine pancreatic cancer

Hwang

Jeong

Yoon

et al. 2021

Preprint

View full text Add to dashboard Cite

Pancreatic cancers are classified based on where they occur into those derived from exocrine glands and endocrine glands, thereby showing different anti-cancer effect with medication. Therefore, it is necessary to develop anti-cancer drugs that can inhibit both of these types. To this end, we developed a heparin-taurocholate conjugate, i.e., LHT, to suppress tumor growth via its anti-angiogenic activity. Here we conducted a study to determine the anti-cancer efficacy of LHT on various types of pancreatic cancer, i.e., human pancreatic ductal adenocarcinoma (PDAC) and human pancreatic neuroendocrine tumor (PNET), at orthotopic animal model. LHT reduced not only proliferation of all three cancer cells, but also attenuated the production of VEGF through ERK dephosphorylation. Especially, these effects of LHT were much stronger to PNET (RINm cells). Also, LHT effectively reduced the migration, invasion and tube formation of endothelial cells via dephosphorylation of VEGFR, ERK1/2, and FAK protein. Eventually LHT reduced strongly ~ 50% tumor weights and tumor volumes of all three cancer cells at orthotopic model via anti-proliferation of cancer cells and anti-angiogenesis of endothelial cells. Interestingly, LHT was highly effective to PNET tumor tissue in vivo. Collectively, these findings demonstrated that LHT could be a potential anti-pancreatic cancer medication, regardless of pancreatic cancer types.

show abstract

Power doppler endoscopic ultrasound for the assessment of pancreatic neuroendocrine tumors

Cited by 13 publications

References 0 publications

Anticancer Effect of Heparin–Taurocholate Conjugate on Orthotopically Induced Exocrine and Endocrine Pancreatic Cancer

Anticancer Effect of Heparin–Taurocholate Conjugate on Orthotopically Induced Exocrine and Endocrine Pancreatic Cancer

Clinical impact of strain histogram EUS elastography and contrast-enhanced EUS for the differential diagnosis of focal pancreatic masses: A prospective multicentric study

Anti-cancer effect of orally absorbable heparin on orthotopically induced exocrine and endocrine pancreatic cancer

Contact Info

Product

Resources

About